Lonza delivers 5.6% CER sales growth and 30% CORE EBITDA margin
Good momentum in commercial CDMO business
Good momentum in commercial CDMO business
This transformation will enable GE HealthCare to build a strong foundation for business growth
USFDA concludes inspection at Zydus' formulation manufacturing facility at SEZ 2, Ahmedabad
This acquisition will significantly strengthen Croda’s Beauty Actives portfolio and increases its exposure to targeted prestige segments
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
The €70 million investment will allow the large-scale manufacturing of high-purity reagents for quality control and testing for biopharma customers, increasing annual output by several thousand tons
Dignitaries and delegates commend India’s leadership in Global South during G20 India Presidency
The investment is part of Croda’s continuing commitment to develop high performance pharmaceutical ingredients and technologies for life sciences.
Subscribe To Our Newsletter & Stay Updated